Baylor College of Medicine’s Center for Globalization announces newest
- This topic has 5 replies, 4 voices, and was last updated 11 years, 8 months ago by
.
-
Posts
-
Thank you so much for sharing this. I save all this info…it’s makes me glad when there is research going on especially related to liver flukes (my dad was in Vietnam).
And being from CA with all the things you hear about fish…I pointed it out once at a store when some fish sold there was from Japan after earthquake/tsunami…they said it was ok but shortly after never seen again ~
Willow, interesting you mention Sushi. I don’t want to put words in Percy’s mouth or Sushi but we both have our suspicions. We REALLY don’t know what we are getting inside of fish. Best to stick to our own fin friends like Salmon etc. I also find it strange that more of our members at this time are from East and West Coasts. Mmmm
Yes, these studies are crutial. Seems There’s no way really (in the US) to test for or determine if someone has had liver fluke infection by the time they have CC. I wondered if maybe my sis picked up liver flukes eating sushi but well never know because they don’t test for it.
THANK you Gavin, I so believe this is one major cause and still think Teddy picked it up in Korea. A Sicilian, you know, will eat anything especially if told it is a delicacy!
Baylor College of Medicine’s Center for Globalization announces newest grant recipients.
This year’s grant recipients include:
Dr. Changyi Johnny Chen, professor of surgery at BCM.
Infection with the liver fluke (Opisthorchis viverrini) is endemic in Northeast Thailand and is a cause of Cholangiocarcinoma (CCA), or bile duct cancer. Since 2008, Chen has established an active collaboration with Khon Kaen University to study molecular targets of CCA. The most critical targets for CCA discovered from their collaboration research are cyclophilin A and the ERK pathway. Thus, the current collaborative project is to carry out a preclinical study to test FDA-approved drugs, Cyclosporin A (CypA inhibitor) and Sorafenib (the ERK pathway inhibitor) in cell culture and animal models of CCA. Once this preclinical study is successfully done, this novel targeted therapy will immediately apply to clinical trials in Thailand.
http://www.bcm.edu/news/item.cfm?newsID=6886
- The forum ‘Websites’ is closed to new topics and replies.